Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Total Liabilities (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Total Liabilities for 4 consecutive years, with $21.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 91.95% to $21.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.5 million through Dec 2025, up 91.95% year-over-year, with the annual reading at $21.5 million for FY2025, 91.95% up from the prior year.
  • Total Liabilities for Q4 2025 was $21.5 million at LENZ Therapeutics, up from $16.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $62.9 million in Q2 2023, with the low at $8.7 million in Q3 2024.
  • Average Total Liabilities over 4 years is $22.9 million, with a median of $17.3 million recorded in 2022.
  • The sharpest move saw Total Liabilities skyrocketed 310.29% in 2023, then crashed 85.97% in 2024.
  • Over 4 years, Total Liabilities stood at $25.6 million in 2022, then soared by 142.9% to $62.2 million in 2023, then plummeted by 81.96% to $11.2 million in 2024, then surged by 91.95% to $21.5 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $21.5 million, $16.8 million, and $11.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.